|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide, KLH conjugated.|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS, pH 7.7|
|Contains||0.01% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:100-1:200|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (Paraffin) (IHC (P))||See 1 publications below|
PA1-32503 detects CXCR3 from human samples.
PA1-32503 has been successfully used in immunohistochemistry (paraffin tissue) applications.
The PA1-32503 immunogen is synthetic peptide, KLH conjugated.
Store at 4°C short term. For extended storage aliquot and store at -20°C or below. Avoid freeze/thaw cycles.
Chemokines play important roles in inflammation and critical for the recruitment of effector immune cells to sites of infection. Historically, CD183 was the third CXC chemokine receptor discovered and therefore, commonly designated as CXCR3. Binding of chemokines to CD183 induces cellular responses that are involved in leukocyte traffic, most notably integrin activation, cytoskeletal changes and chemotactic migration. The CXC chemokine receptor (CXCR) 3, a G-protein-coupled 7-transmembrane receptor, is expressed at high levels on activated and memory T cells, B cells, natural killer cells, and plasmacytoid monocytes.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Serum levels of CXCR3 ligands predict T cell-mediated acute rejection after kidney transplantation.
PA1-32503 was used in immunohistochemistry - paraffin section to measure CXCR3 ligands in the serum of renal allograft recipients
|Huang H,Xu X,Yao C,Cai M,Qian Y,Wang X,Shi B||Molecular medicine reports (9:45)||2014|